Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Papillomavirus Infections 1Hepatitis C, Chronic 1Fibrosis 1Condylomata Acuminata 1Carcinoma, Hepatocellular 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × INDUSTRY × Viusid × Clear all
NCT03584308 2019-05-22

Efficacy of VIUSIDĀ® Plus GLIZIGENĀ® in Patients With Papilloma Virus Esophageal

Catalysis SL

Phase 2 Completed
110 enrolled

Papillomavirus Infections

NCT01111344 2012-05-08

Glizigen-Viudid-External Anogenital Warts in Children and Adolescents

Catalysis SL

Phase 3 Completed
76 enrolled

Condylomata Acuminata

NCT00502086 2011-02-11

Efficacy and Safety of Viusid in Patients With Hepatic Cirrhosis Secondary to Hepatitis C Virus Infection.

Catalysis SL

Phase 3 Completed
100 enrolled
Gastrointestinal

Fibrosis, Carcinoma, Hepatocellular, Hepatitis C, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon ⚔